AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma, Inc. Class A (AEON)
Company Research
Source: GlobeNewswire
IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today reported the grants in December totaling 392,158 restricted stock units (RSUs) of the Company’s common stock to newly hired non-executive employees of the Company. The awards were approved by the Company’s Board of Directors under the Company’s 2025 Inducement Incentive Plan, with a grant date of December 11, 2025 and vesting commencement dates in December 2025. The RSUs vest over four years, 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant. The awards are being granted as inducement material to new employees entering into employment wit
Show less
Read more
Impact Snapshot
Event Time:
AEON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEON alerts
High impacting AEON Biopharma, Inc. Class A news events
Weekly update
A roundup of the hottest topics
AEON
News
- AEON Biopharma Announces Execution of Exchange Agreement with DaewoongGlobeNewswire
- AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting SchedulingGlobeNewswire
- AEON Biopharma (NASDAQ:AEON) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued GrowthGlobeNewswire
- AEON Biopharma (NASDAQ:AEON) had its "buy" rating reaffirmed by analysts at Aegis. They now have a $7.20 price target on the stock.MarketBeat
AEON
Sec Filings
- 12/19/25 - Form PRE
- 12/15/25 - Form 8-K
- 12/4/25 - Form 8-K
- AEON's page on the SEC website